17 completed, 4 recruiting, 3 terminated, 2 active not recruiting. 21 Phase 1, 14 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 21 | Completed 14, Recruiting 3, Active not recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 14 | Completed 7, Recruiting 3, Terminated 3, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Oncovir, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer AGEN2373, Balstilimab, Cyclophosphamide - Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 38 | 2025-05-27 | 2025-12-03 |
| Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC Poly ICLC, IVIG - Stage IV NSCLC | Phase 1 / Phase 2 | Withdrawn | VA Office of Research and Development | 2024-06-04 | 2024-09-19 | |
| Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC Peptide vaccine - NSCLC Stage IV, ALK Fusion Protein Expression | Phase 1 / Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 12 | 2024-05-13 | 2026-07-28 |
| Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance Poly-ICLC intramuscular (IM) injection, Poly-ICLC, Intertumoral (IT) injection - Prostate Cancer Patients on Active Surveillance | Phase 2 | Recruiting | Ashutosh Kumar Tewari | 114 | 2024-01-16 | 2024-04-02 |
| A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL. NeoVax, Cyclophosphamide, Pembrolizumab - Lymphocytic Leukemia | Phase 1 | Recruiting | Dana-Farber Cancer Institute | 15 | 2021-08-18 | 2026-05-28 |
| Nasal Poly-ICLC (Hiltonol®) in Healthy COVID-19 Vaccinated Adults Poly-ICLC (Hiltonol®) or Placebo - COVID - 19 | Phase 1 | Completed | Oncovir, Inc. | 43 | 2021-07-21 | 2023-05-18 |
| Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma Safety, Expansion Cohort - Malignant Pleural Mesothelioma | Phase 1 | Completed | Oncovir, Inc. | 19 | 2020-08-19 | 2025-06-24 |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration - Recurrent Glioblastoma | Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 46 | 2020-01-08 | 2026-08-31 |
| Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations NKTR-214 (Cohort A), Nivolumab (Cohort A, B and C), Stereotactic body radiation therapy (SBRT) (Cohort B) - Metastatic Castration-resistant Prostate Cancer | Phase 1 | Completed | Parker Institute for Cancer Immunotherapy | 43 | 2019-06-21 | 2024-04-12 |
| NeoVax Plus Ipilimumab in Renal Cell Carcinoma NeoVax, Ipilimumab - Kidney Cancer | Phase 1 | Active not recruiting | Patrick Ott, MD, PhD | 19 | 2019-03-03 | 2026-02-03 |
| Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1 Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months - Solid Cancer | Phase 1 / Phase 2 | Terminated | Oncovir, Inc. | 7 | 2018-09-25 | 2021-02-01 |
| Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma Poly-ICLC, Tumor Treating Fields, Peptides - Glioblastoma | Phase 1 | Active not recruiting | Adilia Hormigo | 13 | 2018-03-01 | 2026-09-21 |
| Pembrolizumab + Poly-ICLC in MRP Colon Cancer pembrolizumab, Poly-ICLC - Metastatic Colon Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Asha Nayak | 42 | 2018-01-10 | 2024-06-07 |
| Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer Intratumoral (IT) Poly ICLC 0.5 mg, Intratumoral (IT) Poly ICLC 1.0 mg, Intramuscular (IM) Poly ICLC - Prostate Cancer | Phase 1 | Completed | Ashutosh Kumar Tewari | 13 | 2017-06-16 | 2022-09-10 |
| A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence DC Vaccine, Montanide Vaccine, Poly-ICLC - Melanoma | Phase 2 | Completed | Nina Bhardwaj | 36 | 2015-07-01 | 2022-09-15 |
| In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® Hiltonol - Melanoma, Head and Neck Cancer | Phase 2 | Completed | Oncovir, Inc. | 26 | 2015-03-01 | 2020-12-17 |
| Enhancement by Poly-ICLC During HIV-1 Infection Arm A: Poly-ICLC, Arm B: Normal Saline - HIV-1 Infected Adults With Chronic HIV-1 Infection | Phase 1 / Phase 2 | Completed | Nina Bhardwaj | 15 | 2014-04-01 | 2018-03-13 |
| Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC) Poly-ICLC - Melanoma, Squamous Cell Carcinoma of the Head and Neck | Phase 2 | Terminated | Nina Bhardwaj | 8 | 2013-11-01 | 2018-01-23 |
| Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma IMA 950, Poly ICLC, Immunomonitoring - CNS Tumor, Adult | Phase 1 / Phase 2 | Completed | University Hospital, Geneva | 19 | 2013-08-01 | 2016-04-20 |
| A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS), MELITAC 12.1 + Montanide ISA-51 + polyICLC - Melanoma | Phase 1 | Completed | Craig L Slingluff, Jr | 53 | 2012-10-01 | 2016-08-12 |
Showing 20 of 27. Sign in to see all of them.
Melanoma (7) · Glioblastoma (3) · Neoplasms (3) · Prostatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Glioma (2) · Pancreatic Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Adenocarcinoma (1) · Astrocytoma (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · COVID-19 (1) · Carcinogenesis (1) · Carcinoma (1)
poly ICLC (19) · pembrolizumab (5) · Nivolumab (3) · Cyclophosphamide (2) · Peptides (2) · Safety (2) · atezolizumab (2) · durvalumab (2) · Immunoglobulins, Intravenous (1) · Injections (1) · Injections, Intramuscular (1) · Ipilimumab (1) · Lipopolysaccharides (1) · Monatide (IMS 3015) (1) · Poly I-C (1)
United States (25) · Canada (1) · Switzerland (1)
Nina Bhardwaj, MD, PhD (6) · David H Smith, MD (2) · Frank Lieberman, MD (2) · Frederick P Smith, MD (2) · Adilia Hormigo, MD, PhD (1) · Andres M Salazar, MD (1) · Anna Pavlick, D.O. (1) · Asha Nayak, MD (1) · Ashutosh K. Tewari, MD (1) · Craig L Slingluff, MD (1) · Dimple Chakravarty, PhD (1) · Elizabeth Miller, MD (1) · Eric Christenson, MD (1) · Farrah Kheradmand, MD (1) · Inhye Ahn, MD (1)
PMID 22065672, PMID 19564349, PMID 20549206, PMID 20615924, PMID 21467219, PMID 23032745, PMID 8727138, PMID 110688, PMID 11440640, PMID 11487589, PMID 14639532, PMID 16011702, PMID 16051812, PMID 16554548, PMID 16625202, PMID 17295916, PMID 17395581, PMID 18073382, PMID 18778201, PMID 18797818, PMID 19355966, PMID 19360120, PMID 19420084, PMID 20038196, PMID 20389020, PMID 20697067, PMID 21135147, PMID 21149657, PMID 21632857, PMID 22086194, PMID 22379685, PMID 23248097, PMID 23785047, PMID 2418164, PMID 24366885, PMID 24484236, PMID 24487185, PMID 24739759, PMID 24777970, PMID 24801836, PMID 24852691, PMID 25281915, PMID 25424847, PMID 26564103, PMID 26870818, PMID 26968202, PMID 27956136, PMID 28158275, PMID 28388966, PMID 29696308
R21AI110736 (1), R21CA117152 (1), R21CA133859 (1), R44CA183075 (1)